AKR.L Regulatory News (AKR)

Akers Biosciences, Inc.

("ABI" or the "Company")

Pricing of Public Offering of Common Stock

Recommencement of Trading in Company on AIM

Further to its announcement of 23 January 2014, Akers Biosciences, Inc. (AIM:AKR) (NASDAQ:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the pricing of an underwritten public offering of 2,727,000 shares (the "Shares") of common stock ("Common Shares") at a public offering price of $5.50 per share (the "Offering"). The Company expects to receive approximately $15,000,000 in gross proceeds, before underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the representative of the underwriters a 45-day option to purchase up to 409,050 additional Common Shares at a price of $5.50 per share, which if taken up would raise an additional $2,250,000. The Shares are scheduled to begin trading on The NASDAQ Capital Market at 2:10 pm Eastern Standard Time (7:10 pm GMT) today, 23 January 2014 under the symbol "AKER". It is expected that the Company's existing 2,167,837 depository interests, representing 2,167,837 Common Shares in the Company (trading in which had been suspended), will be readmitted to trading on AIM at 7:30 am on 24 January 2014.

The Company intends to use the net proceeds received from the offering for general corporate purposes, including working capital, product development and fulfillment, marketing activities, expansion of internal sales organization, further development of sales channels, and other capital expenditures.

The offering is expected to close on 28 January 2014, subject to customary closing conditions.

Aegis Capital Corp. is acting as sole book-running manager for the offering.

A registration statement on Form S-1 relating to the Shares was filed with the Securities and Exchange Commission and is effective. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.

Application will be made for 2,727,000 new depository interests, representing 2,727,000 new Common Shares in the Company, to be issued pursuant to the Offering, to be admitted to trading on AIM. It is expected that these new Ordinary Shares will be admitted to trading on AIM at 8.00 am on 30 January 2014. Following completion of the Offering, the Company's total issued share capital will comprise of 4,894,837 Common Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following completion of the Offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

 For more information: